News for Amplia Therapeutics Limited (ATX.AX)

Published at

Sep 20, 2024 4:36 AM

by smallcaps.com.au

negative

negative

Amplia Therapeutics allocated FDA fast-tracking for pancreatic cancer drug narmafotinib

Melbourne-based Amplia Therapeutics (ASX: ATX) has been granted Fast Track Designation for its narmafotinib advanced pancreatic cancer treatment candidate

ATX.AX

Read more →
Published at

Sep 20, 2024 1:24 AM

by investing.com

negative

negative

FDA FAST TRACK DESIGNATION FOR NARMAFOTINIB IN ADVANCED PANCREATIC CANCER By Investing.com

FDA FAST TRACK DESIGNATION FOR NARMAFOTINIB IN ADVANCED PANCREATIC CANCER

INNMF ATX.AX

Read more →
Published at

Aug 7, 2024 9:22 AM

by themarketherald.com.au

mixed

mixed

ASX Market Close: Index up again, Min Res gains on job loss plan | August 7, 2024

The ASX200 made a small recovery today after the torrid start to the week, closing up a quarter of a per cent to about 7700 points.

MOZ.AX MIN.AX LBT.AX SGQ.AX ATX.AX

Read more →
Published at

Aug 6, 2024 1:27 AM

by themarketherald.com.au

positive

positive

Amplia moves to next stage of cancer drug trial for narmafotinib

Amplia Therapeutics Ltd is set to move further through its Phase 2a trial for cancer drug narmafotinib, with four patients showing a response.

ATX.AX

Read more →
Published at

Jul 3, 2024 3:57 AM

by themarketherald.com.au

negative

negative

Amplia enrols new patients to progress testing for pancreatic cancer drug

Amplia Therapeutics Ltd has enrolled a new group of patients to test the efficacy of its drug narmafotinib in treatment of pancreatic cancer.

ATX.AX

Read more →
Published at

Mar 27, 2024 6:11 AM

by themarketherald.com.au

neutral

neutral

Amplia Therapeutics takes step up in pancreatic cancer treatment

Amplia Therapeutics is on to next step in its pancreatic cancer treatment research after a successful completion of phase 1b of the trial

ATX.AX

Read more →
Published at

Oct 20, 2023 1:46 AM

by themarketherald.com.au

positive

positive

Amplia Therapeutics mints $2.4m R&D tax benefit

Amplia Therapeutics (ASX:ATX) has confirmed a $2.4 million R&D tax benefit on the back of research using the company's FAK inhibitors.

ATX.AX

Read more →
Published at

May 29, 2023 10:51 AM

by prnewswire.com

negative

negative

AMP945 Combined with FOLFIRINOX Enhances Treatment Effects in model of Pancreatic Cancer

HIGHLIGHTS Amplia's highly selective FAK inhibitor AMP945, when used in combination with FOLFIRINOX, enhances survival in a preclinical model of pancreatic...

INNMF ATX.AX

Read more →
Published at

May 22, 2023 5:16 AM

by themarketherald.com.au

mixed

mixed

TMH Spotlight: OncoSil Medical (ASX:OSL) treats first patient in Italy, Iceni Gold (ASX:ICL) strikes high grade gold at Guyer

The ASX opened lower this morning, while majority of the sectors dragged.

ICL.AX ATX.AX OSL.AX

Read more →
Published at

May 22, 2023 3:18 AM

by themarketherald.com.au

positive

positive

Amplia Therapeutics (ASX:ATX) receives grant funding to support research collaboration with CSIRO

Amplia Therapeutics (ASX:ATX) has secured grant funding to support research collaboration with Australia's national science agency, CSIRO.

ATX.AX

Read more →
Published at

May 10, 2023 5:57 PM

by stockhead.com.au

mixed

mixed

Check Up Budget Edition: Which ASX healthcare stocks will reap benefits from the Budget?

Telehealth, mental health and aged care stocks rallied on Wednesday following the Budget announcement which include billions for healthcare.

REG.AX ONE.AX LME.AX JHC.AX GLH.AX 1ST.AX RGS.AX PXSLY PXS.AX PBP.AX OCC.AX MEB.AX MDBIF IVX.AX IPDQF IPD.AX IMM.AX HSC.AX CGS.AX ATX.AX ARUXF ADR.AX ACR.AX VTG.AX VLS.AX SOMNF SOM.AX SCU.AX RNO.AX RHT.AX PGC.AX PCK.AX EYE.AX CMP.AX CAN.AX CAJ.AX BXN.AX AMT.AX

Read more →
Published at

May 10, 2023 5:26 AM

by stockhead.com.au

mixed

mixed

ASX Small Caps Lunch Wrap: Who else is trying to dance on the ceiling this morning?

The ASX has dipped 0.2% this morning as the US braces for CPI data, while Magnum's gone flying thanks to a huge offtake deal with Mitsubishi.

WEL.AX VPR.AX SWKS SIO.AX RDN.AX QRVO PDN.AX OAU.AX NCL.AX MTH.AX MEB.AX MDBIF LOT.AX HLX.AX GRPN GMG.AX GLH.AX FAU.AX DYLLF DYL.AX DDR.AX CPH.AX CLT.AX CLE.AX BXN.AX BAT.AX AVGOP AVGO APXYY APX.AX APPEF AGE.AX AAPL MMMKF FYI.AX FTC.AX ENT.AX ATX.AX SCU.AX IVX.AX BUB.AX AJQ.AX AEV.AX

Read more →
Published at

Apr 30, 2023 7:20 PM

by stockhead.com.au

mixed

mixed

Check Up: Healthcare is ripe for AI disruption, and Telix Pharma’s first $100m+ quarterly sales

The healthcare sector is ripe for disruption and artificial intelligence will play a big part in future drug discovery.

PSQ.AX PGC.AX OSX.AX OPT.AX OPT NOXOF NOX.AX IUGNF IMU.AX GSS.AX CYP.AX CKDXF BPH.AX ATX.AX 4DX.AX ZNO.AX SCU.AX RSH.AX PXSLY PXS.AX PAB.AX OCC.AX NC6.AX KZA.AX KMLXF IHL.AX IDT.AX FDMDF DVL.AX CMP.AX BITRF BIT.AX ARUXF AMT.AX ACR.AX 1AD.AX ZLD.AX VTG.AX VLS.AX UBI.AX TD1.AX SOMNF SOM.AX RNO.AX RHY.AX RHT.AX RGS.AX RAC.AX PYC.AX PNV.AX PCK.AX PBP.AX OVN.AX OSL.AX ONE.AX OIL.AX NYR.AX NXSCF NXS.AX MXC.AX MX1.AX MVF.AX MEM.AX MEB.AX MDR.AX MDC.AX MDBIF LBT.AX IVX.AX IPDQF IPD.AX IMRNW IMRN IMM.AX IMC.AX ICR.AX HCT.AX GTG.AX GLH.AX EYE.AX DXB.AX CSL.AX CPH.AX CGS.AX CAN.AX CALZF CAJ.AX BXN.AX BWXXF BWX.AX BNOEF BNO.AX AT1.AX ARX.AX AMDHF ALC.AX ADR.AX ADO.AX 1ST.AX

Read more →
Published at

Mar 5, 2023 7:20 PM

by stockhead.com.au

mixed

mixed

Check Up: Almost half a billion US dollars raised to bring back mammoth, dodo, and Tassie tiger

Colossal Biosciences’ plans to bring the Tasmanian tiger and woolly mammoth back to life, but now it’s also betting on the iconic dodo.

TD1.AX RGS.AX RAC.AX FFC.AX EZL.AX PYC.AX PAB.AX OPT.AX OPT MX1.AX CMP.AX CKDXF AMT.AX VTG.AX VLS.AX SOMNF SOM.AX SCU.AX RNO.AX RHT.AX PXSLY PXS.AX PSQ.AX PNV.AX PGC.AX PBP.AX ONE.AX OCC.AX NYR.AX NC6.AX MVF.AX MEM.AX MEB.AX MDBIF LBT.AX IVX.AX IPDQF IPD.AX IMM.AX HCT.AX GTG.AX GSS.AX EYE.AX CGS.AX CAN.AX CALZF CAJ.AX BXN.AX BWXXF BWX.AX BNOEF BNO.AX ATX.AX ARUXF AMDHF ADR.AX ACR.AX

Read more →
Published at

Feb 1, 2023 5:46 PM

by stockhead.com.au

mixed

mixed

Check Up: The FDA refuses to give CBD a green light, but market doesn’t seem to care

The FDA declined regulate CBD-based supplements and food citing safety reasons, but the CBD index keeps going up.

PYC.AX PSQ.AX PGC.AX MSB.AX KZA.AX EYE.AX DVL.AX CAN.AX BXN.AX BNOEF BNO.AX ADO.AX SOMNF SOM.AX RSH.AX RHT.AX RGS.AX OSX.AX OSL.AX ONE.AX OIL.AX NXSCF NXS.AX MEB.AX MDC.AX MDBIF KMLXF IVX.AX IUGNF IMU.AX IDT.AX GLH.AX CYP.AX CMP.AX CAJ.AX AT1.AX ADR.AX 1ST.AX ZNO.AX ZLD.AX VTG.AX VLS.AX UBI.AX TD1.AX SCU.AX RNO.AX RHY.AX RAC.AX PXSLY PXS.AX PNV.AX PCK.AX PBP.AX PAB.AX OVN.AX OPT.AX OPT OCC.AX NYR.AX NOXOF NOX.AX NC6.AX MXC.AX MX1.AX MVF.AX MEM.AX MDR.AX LBT.AX IPDQF IPD.AX IMRNW IMRN IMM.AX IMC.AX IHL.AX ICR.AX HCT.AX GTG.AX GSS.AX FDMDF DXB.AX CPH.AX CKDXF CGS.AX CALZF BWXXF BWX.AX BPH.AX BITRF BIT.AX ATX.AX ARX.AX ARUXF AMT.AX AMDHF ALC.AX ACR.AX 4DX.AX 1AD.AX

Read more →
Published at

Jan 19, 2023 5:50 PM

by stockhead.com.au

mixed

mixed

Check Up: Japan’s startup OUI wants to halve the world’s blindness with its smartphone device

Japanese startup OUI Inc says it is on a mission to halve the world's blindness with its smartphone-based device.

ZNO.AX ZLD.AX RAP.AX PSQ.AX PIQ.AX PBP.AX PAA.AX MXC.AX IPDQF IPD.AX IDT.AX GLH.AX CGS.AX BXN.AX 1AD.AX SOMNF SOM.AX SHL.AX RSH.AX RGS.AX PGC.AX PCK.AX OVN.AX OSX.AX OSL.AX OIL.AX NYR.AX NXSCF NXS.AX MX1.AX MDC.AX LBT.AX KZIA KZA.AX KMLXF IVX.AX IMMP IMM.AX IHL.AX GSS.AX FDMDF DVL.AX CYP.AX CPH.AX CAN.AX BWXXF BWX.AX BPH.AX BNOEF BNO.AX BITRF BIT.AX AT1.AX ARX.AX AKU.TO AKU ADR.AX 4DX.AX 1ST.AX VTG.AX VLS.AX UBI.AX SCU.AX RNO.AX RHY.AX RHT.AX RAC.AX PYC.AX PXSLY PXS.AX PNV.AX PAB.AX OPT.AX OPT ONE.AX OCC.AX NOXOF NOX.AX NC6.AX MVF.AX MEM.AX MEB.AX MDR.AX MDBIF IUGNF IMU.AX IMRNW IMRN IMC.AX ICR.AX HCT.AX EYE.AX DXB.AX CMP.AX CKDXF CALZF CAJ.AX ATX.AX ARUXF AMT.AX AMDHF ALC.AX ADO.AX ACR.AX

Read more →
Published at

Jan 4, 2023 6:02 PM

by stockhead.com.au

mixed

mixed

Check Up: Moderna posts crazy cancer vaccine results, says melanoma recurrence down by almost half

Moderna’s stock price rose in late December after the company revealed that a vaccine for melanoma showed encouraging results.

TD1.AX RSH.AX PCK.AX MX1.AX KMLXF DVL.AX CAJ.AX BNOEF BNO.AX ARX.AX ADR.AX 1ST.AX ZNO.AX RHY.AX RAC.AX PYC.AX PSQ.AX PGC.AX OVN.AX OSX.AX ONE.AX OCC.AX NOXOF NOX.AX NC6.AX MDC.AX KZA.AX IPDQF IPD.AX IDT.AX GTG.AX CYP.AX CPH.AX CAN.AX BXN.AX BWXXF BWX.AX BPH.AX BITRF BIT.AX ATX.AX ZLD.AX VTG.AX VLS.AX UBI.AX SOMNF SOM.AX SCU.AX RNO.AX RHT.AX RGS.AX PXSLY PXS.AX PNV.AX PBP.AX PAB.AX OSL.AX OPT.AX OPT OIL.AX NYR.AX NXSCF NXS.AX MXC.AX MVF.AX MEM.AX MDR.AX LBT.AX IVX.AX IUGNF IMU.AX IMRNW IMRN IMM.AX IMC.AX IHL.AX ICR.AX HCT.AX GSS.AX GLH.AX FDMDF EYE.AX DXB.AX CMP.AX CKDXF CGS.AX CALZF AT1.AX ARUXF AMT.AX AMDHF ALC.AX ADO.AX ACR.AX 4DX.AX 1AD.AX

Read more →
Published at

Jan 2, 2023 4:30 PM

by prnewswire.com

mixed

mixed

Propulsion of Pancreatic Cancer Pipeline as Novel and Extensive 170+ Therapies Likely to Enter in the Treatment Domain | DelveInsight

/PRNewswire/ -- DelveInsight's 'Pancreatic Cancer Pipeline Insight – 2022' report provides comprehensive global coverage of available, marketed, and pipeline...

INNMF ATX.AX XBIT PBLA INCY I1NC34.SA GRTX BNTXN.MX BNTX BLRX.TA BLRX 600276.SS 0J9P.L 0A3M.L TRVXO.OL TRVX.OL SGEN RCUS QLGN NUVB-WT NUVB MRUS LLY.MX LLY.DE LLY.BA LLY LILY34.SA IBRX AGEN 9995.HK 4575.T 0RIS.L 0Q1G.L 0A8R.L

Read more →
Published at

Nov 30, 2022 8:10 PM

by stockhead.com.au

mixed

mixed

Check Up: The world's most expensive drug costs $3.5 MILLION a shot

The US FDA has just approved the world’s most expensive drug. CSL Behring’s hemophilia B gene therapy costs US$3.5m a dose.

PAB.AX OCC.AX NC6.AX MDR.AX IMM.AX GTG.AX GSS.AX EYE.AX CSLN.MX CSLLY CSL.AX CMXHF BPH.AX SHL.AX RAC.AX PSQ.AX ONE.AX NYR.AX NXSCF NXS.AX MXC.AX KZA.AX FDMDF DXB.AX DVL.AX CYP.AX CPH.AX CGS.AX AT1.AX ARX.AX ARUXF AMDHF ALC.AX ACR.AX 4DX.AX ZNO.AX ZLD.AX VTG.AX VLS.AX UBI.AX TD1.AX SOMNF SOM.AX SCU.AX RSH.AX RNO.AX RHY.AX RHT.AX RGS.AX PYC.AX PXSLY PXS.AX PNV.AX PGC.AX PCK.AX PBP.AX OVN.AX OSX.AX OSL.AX OPT.AX OPT OIL.AX NOXOF NOX.AX MX1.AX MVF.AX MEM.AX MEB.AX MDC.AX MDBIF LBT.AX KMLXF IVX.AX IUGNF IPDQF IPD.AX IMU.AX IMRNW IMRN IMC.AX IHL.AX IDT.AX ICR.AX HCT.AX GLH.AX CMP.AX CKDXF CAN.AX CALZF CAJ.AX BXN.AX BWXXF BWX.AX BNOEF BNO.AX BITRF BIT.AX ATX.AX AMT.AX ADR.AX ADO.AX 1ST.AX 1AD.AX

Read more →
Published at

Nov 23, 2022 7:50 PM

by stockhead.com.au

mixed

mixed

How out of favour Biotech has a PR problem and could learn from Dr Karl

ASX health stocks have fallen out of favour in 2022 with a a rotation out of growth into value sectors but could it also do with better PR?

VTG.AX NEU.AX MXC.AX KZA.AX CSL.AX COH.AX BWXXF BWX.AX AT1.AX ADR.AX ADO.AX ZNO.AX ZLD.AX UBI.AX TD1.AX SHL.AX RSH.AX RHT.AX RAC.AX PNV.AX PBP.AX OVN.AX OSX.AX OSL.AX OCC.AX NOXOF NOX.AX MVF.AX MEM.AX MEB.AX MDC.AX MDBIF LBT.AX KMLXF IUGNF IMU.AX ICS.AX ICR.AX EYE.AX CPH.AX CMP.AX CALZF BXN.AX AMDHF 1ST.AX VLS.AX SOMNF SOM.AX SCU.AX RNO.AX RHY.AX RGS.AX PYC.AX PXSLY PXS.AX PSQ.AX PGC.AX PCK.AX PAB.AX OPT.AX OPT ONE.AX OIL.AX NYR.AX NXSCF NXS.AX MX1.AX MDR.AX IVX.AX IPDQF IPD.AX IMRNW IMRN IMM.AX IMC.AX IHL.AX IDT.AX HCT.AX GTG.AX GSS.AX GLH.AX FDMDF DXB.AX DVL.AX CYP.AX CKDXF CGS.AX CAN.AX CAJ.AX BPH.AX BNOEF BNO.AX BITRF BIT.AX ATX.AX ARX.AX ARUXF AMT.AX ALC.AX ACR.AX 4DX.AX 1AD.AX

Read more →